

**Europe's
leading
API Conference**

Authority Speakers:

Olivier Gross

EMA, United Kingdom

Susanne Keitel

EDQM, France

Keith McDonald

MHRA, United Kingdom

Moheb Nasr

FDA, USA

Lionel Viornéry

AFSSAPS, France

And others invited

Industry Speakers:

Marieke van Dalen

N.V. Organon, part of Schering-Plough, The Netherlands

Rainer Fendt

BASF, Germany

Sepe de Gelas

Amgen, Belgium

Charles Hu

BimSiframGroup, France

Sian Ives

Lhasa Limited, United Kingdom

Julie Maréchal

European Generic Medicines Association, Belgium

Iain Moore

Croda, United Kingdom

Mary Oates

Pfizer, USA

Kou Ohirabaru

Pharma Registrations, Japan

Chris Oldenhof

DSM Anti-Infectives, The Netherlands

Stephan Rosenberger

Lonza Peptides, Belgium

Peter Rossmannith

BASF, Germany

Bernd Schade

Bayer Healthcare, Germany

Jan Smeets

DSM Anti-Infectives, The Netherlands

Hilde Vanneste

Janssen Pharmaceutica, Belgium

Rebecca Wang

Bayer Healthcare, China

Brant Zell

Cherokee Pharma, USA

APIC Active Pharmaceutical
Ingredients Committee

a sector group of



**12th APIC/CEPIC
European Conference on
Active
Pharmaceutical
Ingredients**

18-20 November 2009, Venice, Italy

GMP Conference

18-19 November 2009

Regulatory Affairs Conference

19-20 November 2009

12th APIC/CEFIC European Conference on Active Pharmaceutical Ingredients

Objective

The APIC/CEFIC Conference on Active Pharmaceutical Ingredients is Europe's leading event. Many major stakeholders from Authorities and the Industry are each year joining this Conference. Speakers from FDA, European Commission, EMEA, EDQM, National Authorities and from Industry and Trade will discuss the latest developments in the field of GMP and Regulatory Compliance.

The API industry operates in a complex regulatory framework that is currently going through a process of profound change. API manufacturers as well as manufacturing authorisation holders are facing new global challenges regarding GMP and regulatory compliance. One of the major challenges is that compliance levels established at the various API sites worldwide may differ considerably. Rogue APIs - not manufactured under compliant conditions and/or not even by the supposed manufacturer - raise substantial safety concerns regarding the medicinal products that contain them. The establishment of an efficient and effective system for the enforcement of API compliance and an improved surveillance will become the key issue for the years to come.

The two most prominent Regulatory Authorities in the western world are today still using different approaches to oversee the quality of APIs. While in Europe the manufacturer of the medicinal product - and on his behalf the Qualified Person - needs to assure API-GMP and Regulatory compliance the US FDA rely on their own inspections of the API manufacturers' sites. Both systems are currently trying to cope with the globalisation of API manufacture that has rapidly taken place. More evidence is continually accumulating that the inroad of Rogue APIs into the European market may be quite large. The current legislative initiatives on both sides of the Atlantic are both aiming to reinforce the systems and to establish oversight that will adequately protect the patients against potentially harmful and - as illustrated by e.g. the recent heparin affair - possibly even deadly APIs.

The APIC/CEFIC Conference is the leading international forum for discussions on these important new developments. In addition, the conference will inform attendants in detail about the latest and to be expected regulatory developments through presentations by representatives from major authorities. Moreover, six parallel sessions will provide the opportunity for an in-depth discussion on specific GMP and Regulatory Affairs topics.

GMP Conference

Objectives

The GMP Conference provides updates from the European and US Authorities on recent initiatives, activities as well as expectations and interpretations related to GMP compliance of API manufacturing.

In addition the activities connected with the new Joint International API Inspections Pilot Program will be presented.

Hear from the decision makers from the authorities and industry their views on how to secure the supply chain's integrity. Moreover, the current API compliance situation in China will be a key topic.

The specific GMP and Regulatory Affairs topics to be discussed in the Parallel Sessions will relate to the eCTD, Quality Agreements, Genotoxic Impurities, Atypical APIs, Regulatory issues concerning Japan and several other topical, practical Regulatory issues.

■ An Inspector's View on API Supply Chain Integrity

- What is needed from a regulatory perspective to ensure full supply chain integrity of APIs
- What are the authorities expectations of Industry to ensure full supply chain integrity of APIs
- What impact has the concern of counterfeit APIs had to the approach and scope of inspections by European authorities
- Implications to inspections from the proposal to amend Directive 2001/83/EC
- Global supply of APIs - what is the future environment of inspections and the application of risk management to inspections and programmes

■ Supply Chain Integrity: View from a large Innovator Company

- What is needed from a regulatory perspective to ensure full supply chain integrity of APIs
- What are the authorities expectations of Industry to ensure full supply chain integrity of APIs
- What impact has the concern of counterfeit APIs had to the approach and scope of inspections by European authorities
- Implications to inspections from the proposal to amend Directive 2001/83/EC
- Global supply of APIs - what is the future environment of inspections and the application of risk management to inspections and programmes

■ Securing Supply Chain Integrity: A Regulator's View

- **Securing Supply Chain Integrity: The Role of QMS**
 - Key elements of a Quality System for API Manufacturer
 - What are the benefits of securing supply chain integrity?
 - The multiple systems challenge along the supply chain
 - Supply Chain Quality System – a vision for future

- **Yes We Can: US and EU to include Asia in the Pharmaceutical Surveillance on APIs**
 - Risk evaluation for health protection of EU population related to APIs
 - Criteria, categories, priorities
 - Surveillance effort in the EU
 - Money well spent?
 - Reality versus logic
 - Systematic surveillance in Asia by high standard countries
 - It's possible or how to do?
 - Expectations of results
 - Inspections – answer to all questions?
 - Quality system issues vs. criminal intentions
 - Improvements possible – also for inspection approach
 - Better understand specific challenges
 - Classical inspection
 - Why extend focus?
 - Completion by combining information like yield, batch size, consumption of raw materials etc.
 - Optimise planning of inspections
 - Beyond inspections
 - Considerations for raw material testing
 - Yes we can!

- **Improved Surveillance? Report of the Actual API Compliance Situation in China**

- **The Joint International API Inspections Pilot Program**

- Joint Audit programme status
- Outcome of the inspection within EEA
- Outcome of the inspection outside EEA
- EUDRA GMP database – status
- MRA status
- Inspectors training and qualification plan status

- **Supply Chain Integrity: the Role of Distributor with Current and Future EU Regulator Environment**

- API supply chain integrity
 - Whole control of supply chain from manufacturer of API to end user
 - Risks from manufacturer
 - Risks from end user
 - Risks from other actors in the supply chain
- API compliance in China
 - Key words about China
 - API industry
 - Sales and export
 - Regulatory situation
 - Problems

- Regulation or regulatory practices in EU & USA
 - EU practices and problems
 - US practices with FDA approval
- Role of API distributor
 - Qualification of structure by EU Authority
 - Selecting, auditing and supplying validated APIs
 - Qualifying other intermediate actors
 - Coordination between API manufacturer and end-user/authorities
 - Transparent information
 - Preparation of audit, inspection
 - Regulatory monitoring
- Suggestions and conclusion



Joint GMP and Regulatory Affairs Day

Parallel Sessions I

Session 1:

eCTD at API manufacturers: A case study

- Regulations: guidelines and timelines
- Documents: lifecycle and attributes
- Dossiers: creation and maintenance for authorities and customers
- eCTD as internal format
- Introducing an eCTD system

Session 2:

Quality agreements between API suppliers and customers

- Legal / Regulatory background
- The issue: significant workload for API suppliers and customers by writing, reviewing and discussing Quality Agreements
- The solution: standardised templates
- APIC's Quality Agreement project: status and implementation
- Cooperation with other stakeholders

Session 3:

Topical Regulatory API issues

Parallel Sessions II

Session 4

Aspects of Japanese Regulatory guidance, accreditation and GMP compliance

- Application for Accreditation of Foreign manufacturers
 - What accreditation is
 - Type of accreditations
 - When should an applicant request for an accreditation
 - Documentation needed
 - Accreditation renewal
- Guidance on Master File system
 - When is a Master File needed
 - Master File composition
 - Procedure for changes in Master File
- GMP Compliance Inspections of API manufacturers
 - What triggers an inspection
 - Flow of a GMP compliance inspection
 - Japanese Authority expectations

Session 5

Using in silico toxicity prediction programs to aid the assessment of genotoxic impurities

- A short introduction to in silico toxicity prediction
- Assessment of impurities using a knowledge-based toxicity prediction program
 - Supporting information provided by the program
 - Validation studies carried out on the program
- Using a toxicity database as an additional data source for GI assessment

Genotoxic Impurities – follow-up session

Session 6

Compliance aspects of “Atypical APIs”

- What is an Atypical Active?
- What characteristics does it have?
- Current authority expectations for APIs – does this cause a concern for industry?
- How should atypical APIs be treated differently to other APIs from a regulatory and quality perspective?
- How do you qualify an Atypical Active Supplier?
- Should audits of such APIs be performed in the same manner as other APIs?
- How should all parties (supplier and user) apply a risk based approach for supporting QP declarations

■ A view from the European Generic Medicines Industry on API aspects of the EU Draft Directive on Falsified Medicines

- API supply chain integrity
- Counterfeit/Falsified medical products
- EGA perspective on the API part of the draft Directive
- Pilot USFDA-TGA-EU
- EC communication on “Safe, Innovative and Accessible Medicines”
- Future development

■ A view from APIC & EFCG on API aspects of the EU Draft Directive on Falsified Medicines

- Current problems with Rogue APIs and Façade constructions
- Parallel API regulatory developments in the EU and the US
- APIC & EFCG’s view on the Draft Directive
- The International API Inspection Pilot
- CEFIC’s 10 Points
- The way forward

■ US API industry prospective on “Globalization” and Proposed US legislation

- Background information, brief description of existing legislation (21 CFR)
- Effect of “Globalization” and inability for authorities to handle the shift
- Summary of legislation proposals: Dingell Bill, Kennedy Bill, others?
- API industry position on the proposed legislation and necessary steps forward to ensure a safe drug supply

■ FDA Update on Pharmaceutical Quality Initiatives

- Regulatory Agreements
 - Where are they applicable
 - Benefits to have regulatory agreements with the agency
 - Which data agency expects to be available
- Validation guide
 - Validation guide – status
 - General principles
 - Process validation activities
 - FDA expectations
 - Documentation required

Regulatory Affairs Conference

Objectives

In the RA conference important aspects of the new Variations Regulation will be discussed. Moreover, EDQM will present the latest developments regarding the CEP procedure and industry will report on its recent experiences with the procedure. An update on the status of the new ICH Q11 initiative will also be presented.

■ The Revised Variations Regulation & Detailed Guideline

■ APIC's view on the Revised Variations Regulation & Detailed Guideline

- What benefit will the new EU variation regulations and supporting guidelines bring for API variations?
- What are the implications of the new procedural aspects?
- Some concerns on how to implement the new regulations
- What opportunities for improvement were not included in the update of the variation regulations/supporting guidelines?
- Latest developments regarding the CEP procedure and EDQM's global inspections

■ Industry's view on the CEP procedure

- Granting of CEP
- Maintenance of CEP
- Application of CEPs in MAAs
- Variations linked to CEPs
- Comparison with ASMF
- Issues for API industry
- Proposals for improvements

■ ICH Q11: Status and APIC view

- Status and next steps of ICH Q11 guideline
- Benefits of applying ICH Q11 principles
- What are the approaches to demonstrating process and product understanding?
- How can ICH Q11 support regulatory relief in the API trade sale environment?

■ Closing Remarks

Chairs

Marieke van Dalen, N.V. Organon, part of Merck, The Netherlands

Matt Moran, PharmaChemical Ireland

Chris Oldenhof, DSM Anti-Infectives, The Netherlands

Anthony Storey, Pfizer, UK

Speakers

Marieke van Dalen, N.V. Organon, part of Schering-Plough, The Netherlands

Rainer Fendt, BASF, Germany

Seppe De Gelas, Amgen, Belgium

Olivier Gross, EMEA, United Kingdom

Charles Hu, BimSiframGroup, France

Sian Ives, Lhasa Limited, United Kingdom

Susanne Keitel, EDQM, France

Julie Maréchal, European Generic Medicines Association, Belgium

Keith McDonald, MHRA, United Kingdom

Iain Moore, Croda, United Kingdom

Moheb Nasr, FDA, USA

Mary Oates, Pfizer, USA

Kou Ohirabaru, Pharma Registrations, Japan

Chris Oldenhof, DSM Anti-Infectives, The Netherlands

Stephan Rosenberger, Lonza Peptides, Belgium

Peter Rossmannith, BASF, Germany

Bernd Schade, Bayer Healthcare, Germany

Jan Smeets, DSM Anti-Infectives, The Netherlands

Hilde Vanneste, Janssen Pharmaceutica, Belgium

Lionel Viornéry, AFSSAPS, France

Rebecca Wang, Bayer Healthcare, China

Brant Zell, Cherokee Pharma, USA

Steering Committee

We would like to express our sincere gratitude to the members of the steering committee for developing the conference:

Gerhard Becker, CONCEPT Heidelberg, Germany

Marieke van Dalen, N.V. Organon, part of Schering-Plough, The Netherlands

Rainer Fendt, BASF, Germany

Ricardo Giralte, Boehringer Ingelheim, Germany

Pieter van der Hoeven, CEFIC, Belgium

Matt Moran, PharmaChemical, Ireland

Nessa Moyles, PharmaChemical, Ireland

Chris Oldenhof, DSM Anti-Infectives, The Netherlands

Luisa Paulo, Hovione, Portugal

Oliver Schmidt, CONCEPT Heidelberg, Germany

Anthony Storey, Pfizer, UK

Hana Tomkova, Zentiva, Czech Republic

Hilde Vanneste, Janssen Pharmaceutica, Belgium

Social Event

The social event has become a tradition and was well appreciated during the past conferences (in Brussels, Hamburg, Vienna, Barcelona, Budapest, Lisbon, Berlin, Prague, Warsaw, and Paris).



We will continue this tradition in Venice and invite all participants and speakers to an entertaining evening outside the hotel followed by a dinner.



Organisation

CONCEPT HEIDELBERG
P.O. Box 10 17 64
69007 Heidelberg, Germany
Phone +49 (0) 62 21/84 44-0
Fax +49 (0) 62 21/84 44 34
info@concept-heidelberg.de
www.concept-heidelberg.de

For question regarding content:

Dr Gerhard Becker (Operations Director) at
+ 49 (0) 6221/84 44 65, or at
becker@concept-heidelberg.de

For questions regarding reservation, hotel, organisation etc.:

Ms Marion Grimm (Organisation Manager) at
+ 49 (0)6221/84 44 18, or at
grimm@concept-heidelberg.de

About CEFIC

CEFIC, the European Chemical Industry Council, is the Brussels-based organisation representing national chemical federations and chemical companies of Europe. All in all, CEFIC represents, directly or indirectly, more than 29,000 large, medium and small chemical companies in Europe, which employ about 1.7 million people and account for nearly one third of world chemical production.

About APIC

APIC is one of CEFIC's Sector Groups, comprising producers of active pharmaceutical ingredients (APIs) and intermediates in Europe. For this reason APIC considers itself to be a very important stakeholder in new EU Regulations and Guidelines related to APIs and intermediates. Our 64 members are located all over Europe and include three national associations: AFAQUIM (Spain), PHARMACHEMICAL IRELAND (Ireland) and SICOS (France).

APIC's key objectives are:

- To promote the use of compliant APIs in medicinal products to ensure patient safety
- To represent the interests of pharmaceutical and chemical companies producing APIs and intermediates in Europe by being recognized experts who advance and influence the global GMP and Regulatory environment.

APIC is very active in communicating and monitoring developments of the active pharmaceutical ingredients industry as well as in defending the APIC views and positions on proposed legislation, regulations and guidelines.

About CONCEPT HEIDELBERG

Founded in 1978, CONCEPT HEIDELBERG is the leading organiser of seminars on pharmaceutical production, quality control, quality assurance and GMP in Germany, Austria and Switzerland. This year, more than 240 events will be organised by CONCEPT HEIDELBERG.

The Venue

Hilton Molino Stucky, Venice is located on the island of Giudecca, just a few minutes by boat from Piazza San Marco and 10km (40 minutes by boat) from Venice Marco Polo Airport.



Nothing is more romantic than arriving in Venice by boat, and there is no better way to arrive at Hilton Molino Stucky Venice! You can reach the hotel by vaporetto water bus or water taxi from your land arrival point or maritime station. In addition, there is a regular complimentary hotel shuttle boat from Hotel Molino Stucky Venice and Piazza San Marco.



If you are arriving in Venice by car, there is easy access from all major motorways. Coming by train you will arrive at the Venezia San Lucia railway station. Hop on a vaporetto water bus or a water taxi to reach Giudecca island and Hilton Molino Stucky Venice.



The major attractions of Venice are all easily accessible from Hilton Molino Stucky Venice. It is only a few minutes by complimentary shuttle boat from the hotel to Piazza San Marco, the Basilica di San Marco, and the Doge's Palace, and from here a short walk takes you to the Grand Canal, the Guggenheim Museum, and the Teatro La Fenice. The Rialto Bridge, halfway along the Grand Canal, is historically regarded as the heart of Venice.

From Hilton Molino Stucky you can easily reach the other islands of the Venice lagoon, including Torcello, with its ancient church, Murano, famous for its beautiful glass, and Burano, known for its brightly-colored houses and hand-made embroidery.

Conference Exhibition



Would you also like to present an exhibition stand? And have your company listed in the conference programme? Please contact Ms Marion Grimm at phone + 49-6221/ 84 44 18, or per e-mail at grimm@concept-heidelberg.de.

Registration

Tuesday, 17 November 2009, 19.00 – 20.00 h or
Wednesday, 18 November 2009, 09.00 h - 10.00 h
Regulatory Affairs Part: Thursday, 19 November 2009, 8.00 - 8.30 h

Conference

Wednesday, 18 November 2009, 10.00 h – 18.00 h
Thursday, 19 November 2009, 08.30 h – 17.45 h
Friday, 20 November 2009, 08.30 h – 14.00 h

Venue

Hilton Molino Stucky
Giudecca 810
30133 Venice, Italy
Phone +39 041 2723 311
Fax: +39 041 2723 490
email: info.venice@hilton.com

Fees

Book the GMP Part (18-19 November) or the Regulatory Affairs Part (19-20 November) separately for the price of € 1,680.- each. Or book all three conference days for the special price of € 1,990.-. The registration fee is payable in advance after receipt of invoice.

Discounts

APIC Members 10%, Inspectorates 25%, ECA Members 5%. **Please note that discounts cannot be combined!**

Accommodation

CONCEPT HEIDELBERG has reserved a limited number of rooms in the conference hotel. Please make your reservation via POG (Personalised Online Group Page: http://www.hilton.com/en/hi/groups/personalized/VCEIHIL_GHEIA/index.jhtml) where you also can modify/cancel your reservation until 1 October 2009 without any penalty. Early reservation is recommended.

Registration

Via the attached reservation form, by e-mail or by fax message. Or you register online at www.api-conference.org

Conference language

The official conference language will be English.

General Terms of Business

If you cannot attend the conference you have two options:
1. We are happy to welcome a substitute colleague at any time.
2. If you have to cancel entirely, we must charge the following processing fees:

Cancellation

- until 2 weeks prior to the conference 10 % of the registration fee.
- until 1 week prior to the conference 50 % of the registration fee.
- within 1 week prior to the conference 100 % of the registration fee.

CONCEPT reserves the right to change the materials, instructors, or speakers without notice or to cancel an event. If the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of fees paid. CONCEPT will not be responsible for discount airfare penalties or other costs incurred due to a cancellation.

Terms of payment: Payable without deductions within 10 days after receipt of invoice.

Important: This is a binding registration and above fees are due in case of cancellation or non-appearance. If you cannot take part, you have to inform us in writing. The cancellation fee will then be calculated according to the point of time at which we receive your message. In case you do not appear at the event without having informed us, you will have to pay the full registration fee even if you have not made the payment yet. **You are not entitled to participate in the conference until we have received your payment (receipt of payment will not be confirmed)!**

If the bill-to-address deviates from the specification to the right, please fill out here:

12th APIC/CEFIC European Conference on Active Pharmaceutical Ingredients

18-20 November 2009, Venice, Italy

I want to take part in

- GMP Part** (18-19 November 2009)
- Regulatory Affairs Part** (19-20 November 2009)
- All three conference days** (18-20 November 2009)

Please choose 2 out of 6 parallel sessions (one choice in Session I and one in Session II)

First choice Second choice (in case your first choice is fully booked)

Parallel Sessions I

- | | | |
|--------------------------|--------------------------|---|
| <input type="checkbox"/> | <input type="checkbox"/> | Session 1: eCTD at API manufacturers: A case study |
| <input type="checkbox"/> | <input type="checkbox"/> | Session 2: Quality agreements between API suppliers and customers |
| <input type="checkbox"/> | <input type="checkbox"/> | Session 3: Topical Regulatory API issues |

Parallel Sessions II

- | | | |
|--------------------------|--------------------------|--|
| <input type="checkbox"/> | <input type="checkbox"/> | Session 4: Aspects of Japanese Regulatory guidance, accreditation and GMP compliance |
| <input type="checkbox"/> | <input type="checkbox"/> | Session 5: Using in silico toxicity programs to aid the assessment of genotoxic impurities |
| <input type="checkbox"/> | <input type="checkbox"/> | Session 6: Compliance aspects of "Atypical APIs" |

Mr Ms Title _____

CONCEPT HEIDELBERG
P.O. Box 10 17 64
Fax +49 (0) 6221/84 44 34

69007 Heidelberg
Germany

First name, surname _____

Company _____ APIC Member Inspectorate

Department _____

Important: Please indicate your company's VAT ID Number _____ **P.O. Number if applicable** _____

Street / P.O. Box _____

City _____ Zip Code _____ Country _____

Phone / Fax _____

E-mail (please fill in) _____